ライフサイエンスコーパス: contrast-enhanced MRI

1 ood-brain barrier permeability using dynamic contrast enhanced MRI.

2 diological diagnosis of HCA will be based on contrast enhanced MRI.

3 brain barrier (BBB) were also observed using contrast-enhanced MRI.

4 l infarction can be accurately determined by contrast-enhanced MRI.

5 icted glymphatic solute exchange measured by contrast-enhanced MRI.

6 -positive skeletal findings were examined by contrast-enhanced MRI.

7 BBB permeability was acquired using dynamic contrast-enhanced MRI.

8 w patterns after BBB opening by using serial contrast-enhanced MRI.

9 ic quantification of early treatment dynamic contrast-enhanced MRI.

10 n using in vivo [Formula: see text]-weighted contrast-enhanced MRI.

11 emotherapy based on pretreatment T1-weighted contrast-enhanced MRI.

12 ing adults with large duct PSC who underwent contrast-enhanced MRI.

13 ng antiangiogenic therapy more reliably than contrast-enhanced MRI.

14 cted of having JIA and showed agreement with contrast-enhanced MRI.

15 rain barrier (BBB) was measured with dynamic contrast-enhanced MRI.

16 ET in glioma patients with (18)F-FDG PET and contrast-enhanced MRI.

17 associated with measurements of synovitis on contrast-enhanced MRI.

18 RB) integrity was also assessed with dynamic contrast-enhanced MRI.

19 sitized for EAE and were monitored by serial contrast-enhanced MRI.

20 es can be noninvasively measured by dynamic, contrast-enhanced MRI.

21 Methods: Dynamic susceptibility contrast-enhanced MRI (31 patients), (18)F-FLT PET (20 p

22 Contrast-enhanced MRI accurately measures scarred and vi

23 without prior infarction underwent cine and contrast-enhanced MRI after successful coronary stenting

24 Scores for synovial inflammation at DWI and contrast-enhanced MRI agreed in 37 of 45 participants (8

25 Contrast-enhanced MRI allows detection of non-enhancing

26 10 patients with early RA underwent dynamic contrast-enhanced MRI and conventional MRI of affected m

27 3 mo was also assessed in 43 patients using contrast-enhanced MRI and CT on the basis of the Respons

28 Contrast-enhanced MRI and diffusion-weighted imaging can

29 els combining radiomic features from dynamic contrast-enhanced MRI and diffusion-weighted imaging had

30 and then paclitaxel for NAST, where dynamic contrast-enhanced MRI and diffusion-weighted MRI were ac

31 After FUS treatment, contrast-enhanced MRI and ex vivo histological staining

32 Notably, T1-weighted contrast-enhanced MRI and grade-specific glioma analyses

33 Using dynamic contrast-enhanced MRI and high-resolution fluorescence m

34 Contrast-enhanced MRI and histopathology indicated safe

35 We used dynamic-contrast-enhanced MRI and kinetic modeling to quantify C

36 valuation of myocardial ischemia and delayed contrast-enhanced MRI and low-dose dobutamine cine MRI f

37 al of this study was to compare the value of contrast-enhanced MRI and O-(2-[(18)F]fluoroethyl)-l-tyr

38 image + 1.96 SDs) for dynamic susceptibility contrast-enhanced MRI and overlaid on T1w-Gd images.

39 quantify myocardial infarct heterogeneity by contrast-enhanced MRI and relate it to an electrophysiol

40 ere compared to the level of BBBD evident in contrast-enhanced MRI and to hypointense regions in T2*-

41 ar ejection fraction 41+/-11%) who underwent contrast-enhanced MRI and VT ablation were included.

42 1 contained pre- and postcontrast sequences (contrast-enhanced MRI), and data set 2 contained precont

43 About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast age

44 he relative performance of CT, extracellular contrast-enhanced MRI, and gadoxetate-enhanced MRI for d

45 in inducing BBB disruption as measured by in contrast-enhanced MRI, and we detected broadband emissio

46 rate the effectiveness of a modified dynamic contrast-enhanced MRI approach we have developed to dete

47 Dobutamine magnetic resonance tagging and contrast enhanced MRI are complementary in assessing fun

48 provide an overview of the potential use of contrast-enhanced MRI as tool for further risk stratific

49 sfer constant and plasma volume from dynamic contrast-enhanced MRI as well as DeltaR(2)* peak and are

50 ats underwent diffusion-weighted and dynamic contrast-enhanced MRI at up to seven time points.

51 Comparison with dynamic contrast-enhanced MRI based on the paramagnetic contrast

52 se To assess whether multiparametric dynamic contrast-enhanced MRI-based radiomic features can help d

53 myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization.

54 igh-grade gliomas are usually monitored with contrast-enhanced MRI, but its diagnostic accuracy is li

55 First-pass contrast-enhanced MRI calf muscle perfusion and (31)P MR

56 We hypothesized that the results of contrast-enhanced MRI can be used to predict whether reg

57 as indeterminate at ultrasonography, dynamic contrast-enhanced MRI can be useful for classification a

58 as indeterminate at ultrasonography, dynamic contrast-enhanced MRI can be useful for classification a

59 as shown that diffusion-weighted and dynamic contrast-enhanced MRI can detect metastases, with some s

60 Taken together, our findings suggest dynamic contrast-enhanced-MRI can be used to diagnose specific m

61 Experiments were performed on the Figshare Contrast-Enhanced MRI (CE-MRI) brain tumor dataset, cons

62 ic performance of (68)Ga-DOTATATE PET/CT and contrast-enhanced MRI (CE-MRI) for the detection of osse

63 hy (CEM) is a more accessible alternative to contrast-enhanced MRI (CE-MRI) in breast imaging, but a

64 nt of acute myocardial infarction defined by contrast-enhanced MRI (ceMRI) relates to early restorati

65 PET/CT is significantly more sensitive than contrast-enhanced MRI (ceMRI), contrast-enhanced CT (ceC

66 Keywords: Breast, PET, Dynamic Contrast-enhanced MRI Clinical trial registration no.

67 Multiparametric contrast-enhanced MRI data were obtained, and quantitati

68 rning model for clinical multiphasic dynamic contrast-enhanced MRI datasets.

69 Dynamic contrast enhanced MRI (DCE-MRI) coupled with a pharmacok

70 erent time points alongside clinical dynamic contrast-enhanced MRI (DCE MRI).

71 on and water diffusivity (ADC) using dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted M

72 laque phenotype in RA patients using Dynamic Contrast-Enhanced MRI (DCE-MRI) and Fludeoxyglucose Posi

73 netics of the BBB permeability using dynamic contrast-enhanced MRI (DCE-MRI) and the resulting payloa

74 lung cancers (NSCLC), who underwent dynamic contrast-enhanced MRI (DCE-MRI) before concurrent chemo-

75 Dynamic contrast-enhanced MRI (DCE-MRI) using intracisternally a

76 Data System (BI-RADS) descriptors of dynamic contrast-enhanced MRI (DCE-MRI).

77 ) within the liver and kidneys using dynamic contrast-enhanced MRI (DCE-MRI).

78 id (Gd-DTPA) as a contrast agent for dynamic contrast-enhanced MRI (DCE-MRI).

79 57 mL, P=0.68), and infarct size by standard contrast-enhanced MRI definitions (P=NS) were similar.

80 Contrast-enhanced MRI demonstrated discrete regions of h

81 Contrast-enhanced MRI demonstrated successful injection

82 Dynamic contrast-enhanced MRI (DEMRI) of actively involved knee

83 On the basis of 3-dimensional contrast-enhanced MRI-derived scar reconstructions, 8 pa

84 oxygenation-level dependent MRI and dynamic contrast-enhanced MRI) did not relate to tumor hypoxia c

85 FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and t

86 The size of healed infarcts measured by contrast-enhanced MRI does not change between 10 and 30

87 geneity, Multiparametric MR Imaging, Dynamic Contrast-enhanced MRI, Dynamic Susceptibility Contrast M

88 the transmural extent of hyperenhancement by contrast-enhanced MRI early after myocardial infarction

89 We have observed 3 abnormal patterns on contrast-enhanced MRI early after reperfused myocardial

90 GBCAs in 5457 pregnancies, representing one contrast-enhanced MRI examination per 860 pregnancies (0

91 inal MRI constituted 22.3% (n = 1536) of all contrast-enhanced MRI examinations during pregnancy.

92 Most contrast-enhanced MRI examinations were performed in the

93 cokinetic parameters at pretreatment dynamic contrast-enhanced MRI exhibited good performance for pre

94 bsequently, contrast-enhanced CT (Fig 2) and contrast-enhanced MRI (Fig 3) were performed.

95 d 10 microg/kg/min of dobutamine followed by contrast-enhanced MRI (first pass and delayed imaging) a

96 were sensitized for EAE, followed by serial contrast-enhanced MRI for 6 months, and then were euthan

97 The results indicate that DWI could replace contrast-enhanced MRI for imaging of synovial inflammati

98 The clinical reproducibility of contrast-enhanced MRI for infarct size determination com

99 The importance of contrast-enhanced MRI for synovitis assessment has been

100 s after radiation therapy because the use of contrast-enhanced MRI for this issue is often difficult.

101 n a loss of barrier integrity was seen using Contrast Enhanced MRI (Gd-DTPA) during the late stage of

102 Conclusion Contrast-enhanced MRI had superior sensitivity and negat

103 The presence of scar measured by contrast-enhanced MRI has been shown to predict poor pro

104 The reproducibility of contrast-enhanced MRI has not been established.

105 After prolonged coronary occlusion, contrast-enhanced MRI identifies myocardial infarction a

106 3 to 15 minutes) hyperenhancement of Gd-DTPA contrast-enhanced MRI images occurs frequently in dysfun

107 Hyperpolarized (13)C MRI and dynamic contrast enhanced MRI in murine tumor models provide use

108 netic resonance imaging (MRI) and the TEI by contrast-enhanced MRI in 31 patients with single-vessel

109 hy (DM), whole-breast ultrasound (WBUS), and contrast-enhanced MRI in a high-risk screening populatio

110 3D scar anatomy derived from high-resolution contrast-enhanced MRI in a swine model of chronic myocar

111 dies assessing the diagnostic performance of contrast-enhanced MRI in detecting breast cancer.

112 We tested the validity of contrast-enhanced MRI in quantifying scarred and viable

113 he number of patients who might benefit from contrast-enhanced MRI in the United States.

114 of Ran-SPION-rIgP/cIgY-MAP2 using molecular contrast-enhanced MRI in vivo and validated neuronal upt

115 We assessed the clinical efficacy of contrast-enhanced MRI in women with primary breast cance

116 T1-weighted contrast-enhanced MRI indicated BBB disruption at the ti

117 uggest that the presence of scar measured by contrast-enhanced MRI is a predictor of arrhythmias and

118 Contrast-enhanced MRI is essential for evaluation of syn

119 Contrast-enhanced MRI is the method of choice for brain

120 Contrast-enhanced MRI is typically used to follow treatm

121 However, performing a full contrast-enhanced MRI is unrealistic because of limited

122 Contrast-enhanced MRI lymphography shows potential to id

123 ues, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, magnetic resonance spectroscopy,

124 WIS) assessment at initial ultrafast dynamic contrast-enhanced MRI may be used to predict pathologic

125 quantifiable change of BRB breakdown by the contrast-enhanced MRI method is ideal to assess the ther

126 A contrast-enhanced MRI method was developed in parallel t

127 rds: CT, Diffusion-weighted Imaging, Dynamic Contrast-enhanced MRI, MRI, Radiomics, Unsupervised Lear

128 Keywords: Dynamic Contrast-enhanced MRI, Myocardial Infarction, MRI, Pharm

129 By 7 days post-PH, contrast-enhanced MRI no longer detected a difference in

130 the brain and paranasal sinuses followed by contrast-enhanced MRI of the brain for further evaluatio

131 the brain and paranasal sinuses followed by contrast-enhanced MRI of the brain for further evaluatio

132 Contrast-enhanced MRI of the brain was also performed (n

133 Contrast-enhanced MRI of the brain was also performed, w

134 nts underwent prone (18)F-FDG PET/CT and 3-T contrast-enhanced MRI of the breast.

135 Unenhanced CT (Fig 1) and contrast-enhanced MRI of the lumbosacral spine were perf

136 Unenhanced CT and contrast-enhanced MRI of the lumbosacral spine were perf

137 Dynamic contrast-enhanced MRI of the sella and pituitary gland (

138 Dynamic contrast-enhanced MRI of the sella and pituitary gland a

139 nhanced CT of the thoracic spine (Fig 1) and contrast-enhanced MRI of the thoracic spine (Fig 2).

140 uded unenhanced CT of the thoracic spine and contrast-enhanced MRI of the thoracic spine.

141 in patients with brain metastasis (BM) since contrast-enhanced MRI often remains inconclusive.

142 Multiphasic contrast-enhanced MRI or CT was obtained before and Brem

143 for studies comparing CT with extracellular contrast-enhanced MRI or gadoxetate-enhanced MRI in adul

144 CT, extracellular contrast-enhanced MRI, or gadoxetate-enhanced MRI could

145 either gadoxetate-enhanced or extracellular contrast-enhanced MRI over CT.

146 rce of interreader variation for all dynamic contrast-enhanced MRI parameters.

147 Using an advanced dynamic contrast-enhanced MRI protocol with high spatial and tem

148 Abbreviated contrast-enhanced MRI protocols can be used as a screeni

149 Then 3 different abbreviated contrast-enhanced MRI protocols were analysed separately

150 We conclude that chimera and molecular contrast-enhanced MRI provide sufficient sensitivity for

151 Contrast-enhanced MRI provides an anatomical correlate t

152 Dynamic contrast-enhanced MRI provides an indication of the exte

153 Second, DWI was compared with contrast-enhanced MRI regarding detection of synovial in

154 By contrast-enhanced MRI, regions of profound microvascular

155 the transmural extent of hyperenhancement by contrast-enhanced MRI, restoration of flow, and recovery

156 BB by low-intensity pFUS+MB, as evidenced by contrast-enhanced MRI, resulted in an immediate damage-a

157 Molecular contrast-enhanced MRI results were confirmed by optical

158 Dynamic contrast-enhanced MRI revealed anti-vascular effects of

159 cord of fingolimod-treated mice; T1-weighted contrast-enhanced MRI revealed intact BBB, whereas T2-we

160 Dynamic contrast-enhanced MRI revealed perturbed angiogenesis ch

161 Simulated and real contrast-enhanced MRI scans demonstrated comparable tumo

162 Post-NACI dynamic contrast-enhanced MRI scans from multiple vendors were a

163 Pretreatment dynamic contrast-enhanced MRI scans obtained using scanners from

164 using both the AB-MRI protocol (ie, dynamic contrast-enhanced MRI scans only) and the full MRI proto

165 sment with that of TIC assessment of dynamic contrast-enhanced MRI scans to categorize adnexal lesion

166 size by using 22 pairs of real and simulated contrast-enhanced MRI scans.

167 ly detection model to detect malignancies on contrast-enhanced MRI scans.

168 with each patient having 100 pelvic dynamic contrast-enhanced MRI scans.

169 hich confound the interpretation of standard contrast-enhanced MRI scans.

170 Contrast-enhanced MRI showed hyperenhancement of myocard

171 Contrast-enhanced MRI showed reproducible and consistent

172 mphatic influx and efflux rates with dynamic contrast-enhanced MRI, showing that glymphatic transport

173 uent imaging findings (contrast-enhanced CT, contrast-enhanced MRI, sonography, or PET/CT follow-up);

174 Conclusion At multiphase contrast-enhanced MRI, substantial necrosis helped ident

175 stography, Neoadjuvant Chemotherapy, Dynamic Contrast-enhanced MRI Supplemental material is available

176 : Tumor Response, Breast, Prognosis, Dynamic Contrast-enhanced MRI Supplemental material is available

177 A new contrast-enhanced MRI technique allows direct visualizat

178 e multiparametric approach contained dynamic contrast enhanced MRI that measured improved vessel feat

179 Moreover, we show with dynamic contrast enhanced MRI that sequential intravenous doses

180 We used dynamic contrast-enhanced MRI to assess the effect of hypertensi

181 ective cohort (N = 50; 68-84 years), we used contrast-enhanced MRI to estimate the permeability-surfa

182 ardiac death, 47 patients underwent cine and contrast-enhanced MRI to measure LV function, volumes, m

183 In humans, we used dynamic contrast-enhanced MRI to quantify blood-brain barrier dy

184 DOTA) into the cisterna magna during dynamic contrast-enhanced MRI to quantify glymphatic transport k

185 We used dynamic contrast-enhanced MRI to study 68 ovarian tumors that we

186 We used dynamic contrast-enhanced MRI to study 68 ovarian tumours that w

187 avoxel incoherent motion imaging and dynamic contrast-enhanced MRI) to assess tumor glucose metabolis

188 days of gestation could be estimated through contrast-enhanced MRI using a long circulating blood-poo

189 Contrast-enhanced MRI using Eu(II)-based contrast agents

190 groups of animals underwent a 40-min dynamic contrast-enhanced MRI using radio frequency spoiled grad

191 articipants; 95% CI: 60%, 90%) with DWI when contrast-enhanced MRI was considered the reference stand

192 Contrast-enhanced MRI was evaluated for technical succes

193 nclusion Quantitative or qualitative dynamic contrast-enhanced MRI was not relevant for Prostate Imag

194 Quantitative three-dimensional analysis of contrast-enhanced MRI was performed to determine thresho

195 Contrast-enhanced MRI was performed to study tumor chara

196 ion, the semiquantitative synovitis grade on contrast-enhanced MRI was significantly associated with

197 Dynamic, contrast-enhanced MRI was used in fully awake rats to fo

198 Dynamic contrast-enhanced MRI was used to visualize CSF-ISF exch

199 Using intrathecal gadolinium contrast-enhanced MRI, we show that contrast-enhanced CS

200 Cine and contrast-enhanced MRI were performed 3 days after the pr

201 ET imaging, T2-weighted MRI, and T1-weighted contrast-enhanced MRI were performed before disease indu

202 Subsequently, contrast-enhanced CT and contrast-enhanced MRI were performed.

203 ications in Medicine data for breast dynamic contrast-enhanced MRI with case-level labels, and its pu